Alexion, AstraZeneca Rare Disease has received the US Food and Drug Administration's (FDA) approval for Voydeya (danicopan) as an add-on therapy to treat extravascular haemolysis (EVH) in adults ...

Smith, A. U., Lancet, ii, 910 (1950). Sloviter, H. A., Lancet, i, 823 (1951). Mollison, P. L., and Sloviter, H. A., Lancet, ii, 862 (1951).

The first-in-class therapy – a targeted factor B inhibitor – was able to "substantially" reduce the destruction of red blood cells (haemolysis) that occurs in PNH when used over 12 weeks as a ...

Danicopan (ALXN2040) has shown its value as an add-on treatment for paroxysmal nocturnal haemoglobinuria (PNH) who experience extravascular haemolysis (EVH) – breakdown of red blood cells in the ...